Literature DB >> 8183440

Effect of chronic antidepressant treatment on 5-HT1B presynaptic heteroreceptors inhibiting acetylcholine release.

F Bolaños-Jiménez1, R Manhães de Castro, G Fillion.   

Abstract

The effect of long term treatment with two tricyclic antidepressants on the sensitivity of 5-HT1B presynaptic heteroreceptors inhibiting acetylcholine (ACh) release was investigated. Groups of male rats received during 14 days either saline, citalopram (20 mg/kg), a serotonin (5-HT) uptake blocker, or tianeptine (2 x 10 mg/kg), an antidepressant that enhances 5-HT uptake. The efficacy of the 5-HT1B selective agonist 7-trifluoromethyl-4-(4-1-piperazinyl)-pyrrolo[1,2-a]quinoxaline (CGS 12066B) in reducing K(+)-evoked [3H]acetylcholine release from hippocampal synaptosomes was determined 24 hr after the last administration. The chronic treatment with citalopram or tianeptine modified neither the basal nor the K(+)-evoked release of [3H]acetylcholine. In contrast, these treatments significantly reduced the efficacy of CGS 12066B to inhibit the release of [3H]acetylcholine induced by K+ depolarization. These data suggest that chronic antidepressant treatment desensitizes 5-HT1B presynaptic heteroreceptors through a mechanism which seems to be independent of the synaptic availability of 5-HT.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8183440     DOI: 10.1016/0028-3908(94)90099-x

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  2 in total

1.  The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.

Authors:  Wei-Li Kuan; Jing-Wei Zhao; Roger A Barker
Journal:  Psychopharmacology (Berl)       Date:  2007-12-23       Impact factor: 4.530

2.  Region-specific regulation of 5-HT1B receptors in the rat brain by chronic venlafaxine treatment.

Authors:  R Vidal; A Diaz; A Pazos; E Castro
Journal:  Psychopharmacology (Berl)       Date:  2013-04-23       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.